Edition:
United Kingdom

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

7.13USD
22 Oct 2018
Change (% chg)

-- (--)
Prev Close
$7.13
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
208,710
52-wk High
$8.13
52-wk Low
$4.12

Latest Key Developments (Source: Significant Developments)

Biocryst Receives $3.5 Mln For Clinical Trials Of Galidesivir In Yellow Fever
Monday, 17 Sep 2018 

Sept 17 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST RECEIVES ADDITIONAL $3.5 MILLION TO FUND CLINICAL TRIALS OF GALIDESIVIR IN YELLOW FEVER.BIOCRYST PHARMACEUTICALS - NIAID DEVELOPMENT CONTRACT FOR GALIDESIVIR NOW TOTALS $43.0 MILLION.  Full Article

Biocryst reports Q2 loss per share $0.19
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.19.Q2 REVENUE $12.5 MILLION VERSUS $3.1 MILLION.Q2 REVENUE VIEW $3.5 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.24 -- THOMSON REUTERS I/B/E/S.FY 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 MILLION TO $105 MILLION.FY 2018 OPERATING EXPENSES TO BE IN RANGE OF $90 MILLION TO $110 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $3.5 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

U.S. FDA Grants Fast Track Designation For Biocryst’S Bcx7353
Monday, 6 Aug 2018 

Aug 6 (Reuters) - BioCryst Pharmaceuticals Inc ::U.S. FDA GRANTS FAST TRACK DESIGNATION FOR BIOCRYST’S BCX7353.BIOCRYST PHARMACEUTICALS - FOCUSED ON COMPLETING PHASE 3 PROGRAM & PREPARING FOR NDA FILING FOR BCX7353 IN H2 2019.  Full Article

BioCryst Pharmaceuticals Commences Public Offering Of Common Stock
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS COMMENCES PUBLIC OFFERING OF COMMON STOCK.  Full Article

Biocryst Pharmaceuticals Entered $30 Million Secured Loan Facility
Friday, 20 Jul 2018 

July 20 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC - CO, UNITS, ENTERED A $30 MILLION SECURED LOAN FACILITY - SEC FILING.BIOCRYST PHARMACEUTICALS - USING PROCEEDS OF NEW LOAN TO PAY OFF OUTSTANDING AMOUNTS UNDER PRIOR CREDIT AGREEMENT.  Full Article

Biocryst Provides Update On Strategy, Pipeline And Outlook
Wednesday, 11 Jul 2018 

July 11 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PROVIDES UPDATE ON STRATEGY, PIPELINE AND OUTLOOK.BIOCRYST PHARMACEUTICALS INC - CONTINUE TO EXPECT TO REPORT TOP-LINE RESULTS FROM 750 MG COHORT IN Q3 OF 2018.BIOCRYST PHARMACEUTICALS INC - EXECUTING A STRATEGIC PLAN.BIOCRYST - ON TRACK FOR H1 2019 INITIATION OF PHASE 1 CLINICAL TRIAL FOR ALK-2 INHIBITOR PROGRAM FOR TREATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA.BIOCRYST PHARMACEUTICALS INC - HAS REVISED ITS STAND-ALONE 2018 GUIDANCE AND EXPECTS ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 TO $105 MILLION.BIOCRYST PHARMACEUTICALS INC - 2018 OPERATING EXPENSES TO BE IN RANGE OF $90 TO $110 MILLION.BIOCRYST PHARMACEUTICALS INC - EXPECT TO REPORT TOP-LINE RESULTS FROM ZENITH-1 750 MG COHORT IN Q3 2018.BIOCRYST PHARMACEUTICALS INC - EXPECTS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $85 TO $105 MILLION.  Full Article

Biocryst Pharmaceuticals Says Merger Agreement Terminated With Idera Pharmaceuticals
Tuesday, 10 Jul 2018 

July 11 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS ANNOUNCES TERMINATION OF MERGER AGREEMENT WITH IDERA PHARMACEUTICALS.BIOCRYST PHARMACEUTICALS INC - TERMINATED PREVIOUSLY ANNOUNCED MERGER AGREEMENT WITH IDERA PHARMACEUTICALS.BIOCRYST PHARMACEUTICALS INC - IN ACCORDANCE WITH TERMS OF MERGER AGREEMENT, BIOCRYST WILL REIMBURSE IDERA FOR TRANSACTION-RELATED EXPENSES OF $6 MILLION.BIOCRYST - TERMINATED MERGER AGREEMENT AFTER BIOCRYST STOCKHOLDERS' FAILURE TO APPROVE ADOPTION OF MERGER AGREEMENT AT SPECIAL MEETING.  Full Article

Great Point Partners Says Delivered Letter To Biocryst Pharma
Wednesday, 20 Jun 2018 

June 20 (Reuters) - BioCryst Pharmaceuticals Inc ::GREAT POINT PARTNERS SAYS DELIVERED LETTER TO BIOCRYST PHARMACEUTICALS REAFFIRMING ITS OBJECTIONS TO PROPOSED MERGER OF BIOCRYST & IDERA PHARMACEUTICALS.  Full Article

Biocryst Urges Stockholders To Vote "For" Merger Transaction With Idera
Tuesday, 5 Jun 2018 

June 5 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST PHARMACEUTICALS INC SAYS URGE STOCKHOLDERS TO VOTE "FOR" MERGER TRANSACTION WITH IDERA PHARMACEUTICALS.  Full Article

Biocryst Pharmaceuticals Q1 Loss Per Share $0.26
Tuesday, 8 May 2018 

May 8 (Reuters) - BioCryst Pharmaceuticals Inc ::BIOCRYST REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.26.Q1 REVENUE $4.0 MILLION VERSUS $9.4 MILLION.Q1 REVENUE VIEW $6 MILLION -- THOMSON REUTERS I/B/E/S.Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S.BIOCRYST CONTINUES TO EXPECT ITS 2018 NET OPERATING CASH USE TO BE IN RANGE OF $67 TO $90 MILLION.  Full Article